期刊
JOURNAL OF NUCLEAR MEDICINE
卷 54, 期 11, 页码 1869-1875出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.112.118612
关键词
HER2-positive breast cancer; trastuzumab; PET; Cu-64; molecular imaging
资金
- from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese Government
The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)-positive tumor images of Cu-64-DOTA-trastuzumab in humans. Methods: PET was performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, and 48 h after injection of approximately 130 MBq of the probe Cu-64-DOTA-trastuzumab. Radioactivity data were collected from the blood, urine, and normal-tissue samples of these 6 patients, and the multiorgan biodistribution and internal dosimetry of the probe were evaluated. Safety data were collected for all the patients after the administration of Cu-64-DOTA-trastuzumab and during the 1-wk follow-up period. Results: According to our results, the best timing for the assessment of Cu-64-DOTA-trastuzumab uptake by the tumor was 48 h after injection. Radiation exposure during Cu-64-DOTA-trastuzumab PET was equivalent to that during conventional F-18-FDG PET. The radioactivity in the blood was high, but uptake of Cu-64-DOTA-trastuzumab in normal tissues was low. In 2 patients, Cu-64-DOTA-trastuzumab PET showed brain metastases, indicative of blood-brain barrier disruptions. In 3 patients, Cu-64-DOTA-trastuzumab PET imaging also revealed primary breast tumors at the lesion sites initially identified by CT. Conclusion: The findings of this study indicated that Cu-64-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据